- Home
- TCRX vs STKS Comparison
TCRX vs STKS Comparison
Compare TCRX & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TCRX | STKS |
|---|---|---|
| Founded | 2018 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 57.1M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | TCRX | STKS |
|---|---|---|
| Price | $1.21 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $7.00 | $4.70 |
| AVG Volume (30 Days) | ★ 1.2M | 44.9K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,325,000.00 | ★ $805,722,000.00 |
| Revenue This Year | N/A | $7.47 |
| Revenue Next Year | $19.81 | $8.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | 19.66 |
| 52 Week Low | $0.88 | $1.65 |
| 52 Week High | $2.57 | $5.19 |
Technical Indicators
Market Signals| Indicator | TCRX | STKS |
|---|---|---|
| Relative Strength Index (RSI) | 53.19 | 45.38 |
| Support Level | $0.93 | $1.67 |
| Resistance Level | $1.21 | $2.03 |
| Average True Range (ATR) | 0.10 | 0.11 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 35.19 | 19.16 |
Price Performance
Historical ComparisonAbout TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through three segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.